Study of Boswellia Serrata for Pain Relief and Safety in People with Knee Osteoarthritis

INTERVENTION: Intervention1: Boswellia Serrata 50 mg: Nutraceuticals, one capsules daily in morning for 180 days Control Intervention1: Etoricoxib 90 mg: Drug, one tablet in the morning for 180 days CONDITION: Health Condition 1: M958‐ Other specified acquired deformities of musculoskeletal system PRIMARY OUTCOME: Mean change in WOMAC total scoreTimepoint: Day 0, 30, 60, 90, 120, 150, 180 SECONDARY OUTCOME: 1. Mean change in WOMAC pain subscale. ; 2. Mean change in WOMAC stiffness scale. ; 3. Mean change in WOMAC physical function scale. ; 4. Mean change in VAS. ; 5. Mean change in EQ5D. ; 6. Mean change in 6MWT. ; 7. Mean change in biomarkers. ; 8. Mean change in physician global assessment. ; 9. Mean change in radiological assessment. ; 10. safety assessment through laboratory, vital sign, physical examination, adverse effects.Timepoint: 1. Day 0, 30, 60, 90, 120, 150, 180 ; 2. Day 0, 30, 60, 90, 120, 150, 180 ; 3. Day 0, 30, 60, 90, 120, 150, 180 ; 4. Day 0, 30, 60, 90, 120, 150, 180 ; 5. Day 0, 30, 60, 90, 120, 150, 180 ; 6. Day 0, 30, 60, 90, 120, 150, 180 ; 7, Day 0, 90, 180 ; 8. Day 0, 30, 60, 90, 120, 150, 180 ; 9. Day 0, 90, 180 ; 10. Day 0, 90, 180 INCLUSION CRITERIA: 1. Men or women aged between 40 to 75 years. 2. Diagnosis of osteoarthritis based on history of clinical findings and radiological findings. 3. Minimum VAS score is more more or equal 4. 4. Patient ambulant and requiring treatment for osteoarthritis. 5. Post operative patients are also eligible. 6. Able to give written informed consent form.